Coronavirus disease 2019 in a psoriatic patient with concomitant chronic obstructive pulmonary disease under treatment with risankizumab.
作者信息
Kiss Norbert, Lőrincz Kende, Medvecz Márta, Fésűs Luca, Csuha Péter, Hermányi Zsolt, Wikonkál Norbert Miklós
机构信息
Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary.
3rd Department of Internal Medicine, Bajcsy-Zsilinszky Hospital, Budapest, Hungary.
出版信息
Dermatol Ther. 2020 Nov;33(6):e14186. doi: 10.1111/dth.14186. Epub 2020 Sep 8.
Abstract
摘要
相似文献
1
Coronavirus disease 2019 in a psoriatic patient with concomitant chronic obstructive pulmonary disease under treatment with risankizumab.
Dermatol Ther. 2020 Nov;33(6):e14186. doi: 10.1111/dth.14186. Epub 2020 Sep 8.
2
COVID-19 Updates: Monoclonal Antibodies for COVID-19.
Med Lett Drugs Ther. 2022 Jan 24;64(1642):16.
3
Coronavirus disease 2019 (COVID-19) rash in a psoriatic patient treated with Secukinumab: Is there a role for Interleukin 17?
Dermatol Ther. 2020 Nov;33(6):e14011. doi: 10.1111/dth.14011. Epub 2020 Jul 27.
4
Alopecia areata in a patient with SARS-Cov-2 infection.
Dermatol Ther. 2020 Nov;33(6):e14295. doi: 10.1111/dth.14295. Epub 2020 Sep 21.
5
[Final recommendations to incorporate efalizumab into the clinical practice].
Actas Dermosifiliogr. 2008 Jan;99 Suppl 1:82. doi: 10.1016/s0001-7310(08)76202-1.
6
Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
Clin Exp Dermatol. 2022 Mar;47(3):561-567. doi: 10.1111/ced.14979. Epub 2021 Nov 17.
7
Biologicals in the treatment of psoriasis.
Curr Opin Investig Drugs. 2007 Nov;8(11):939-46.
8
Guselkumab (Tremfya) for psoriasis.
Med Lett Drugs Ther. 2017 Nov 6;59(1533):179-180.
9
Broadalumab (Siliq)--another IL-17A antagonist for psoriasis.
Med Lett Drugs Ther. 2017 Jul 17;59(1525):118-119.
10
Depression? It's the Disease NOT the Drug.
J Drugs Dermatol. 2018 Aug 1;17(8):s28.
引用本文的文献
1
Weathering the Storm: How Age and Biologics Influence the COVID-19 Cytokine Surge.
Pathogens. 2025 Apr 3;14(4):346. doi: 10.3390/pathogens14040346.
2
Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm.
Int J Mol Sci. 2022 Apr 20;23(9):4545. doi: 10.3390/ijms23094545.
3
Erythrodermic flare-up of psoriasis with COVID-19 infection: A report of two cases and a comprehensive review of literature focusing on the mutual effect of psoriasis and COVID-19 on each other along with the special challenges of the pandemic.
Clin Case Rep. 2022 Apr 20;10(4):e05722. doi: 10.1002/ccr3.5722. eCollection 2022 Apr.
4
Correlation Analysis Between Serum Uric Acid, Prealbumin Level, Lactate Dehydrogenase, and Severity of COVID-19.
Front Mol Biosci. 2021 Jul 12;8:615837. doi: 10.3389/fmolb.2021.615837. eCollection 2021.
5
The signal pathways and treatment of cytokine storm in COVID-19.
Signal Transduct Target Ther. 2021 Jul 7;6(1):255. doi: 10.1038/s41392-021-00679-0.
6
The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments.
Vaccines (Basel). 2020 Dec 2;8(4):728. doi: 10.3390/vaccines8040728.
7
Asymptomatic SARS-CoV2 infection in a patient receiving risankizumab, an inhibitor of interleukin 23.
JAAD Case Rep. 2021 Jan;7:60-61. doi: 10.1016/j.jdcr.2020.10.032. Epub 2020 Nov 6.
本文引用的文献
1
Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19).
Respir Med. 2020 Jun;167:105941. doi: 10.1016/j.rmed.2020.105941. Epub 2020 Mar 24.
2
Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs.
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e360-e361. doi: 10.1111/jdv.16587. Epub 2020 Jun 8.
3
The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.
Br J Dermatol. 2020 Aug;183(2):373-374. doi: 10.1111/bjd.19158. Epub 2020 May 28.
4
SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e254-e255. doi: 10.1111/jdv.16468. Epub 2020 Jun 10.
5
Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic.
Am J Clin Dermatol. 2020 Jun;21(3):307-311. doi: 10.1007/s40257-020-00514-2.
6
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.
BMJ. 2020 Mar 26;368:m1091. doi: 10.1136/bmj.m1091.
7
Should biologics for psoriasis be interrupted in the era of COVID-19?
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
Zotero 插件